This is a working overview of research chemical, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-13. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
== See also == Blood irradiation therapy Chromotherapy Crib A'Glow Free-running sleep Low level laser therapy Neuromodulation Neurostimulation Neurotechnology Photodynamic therapy Sun tanning UV-B lamps
Dedifferentiation () is a transient process by which cells become less specialized and return to an earlier cell state within the same lineage. This suggests an increase in cell potency, meaning that, following dedifferentiation, a cell may possess the ability to re-differentiate into more cell types than it did before dedifferentiation. This is in contrast to differentiation, where differences in gene expression, morphology, or physiology arise in a cell, making its function increasingly specialized. The loss of specialization observed in dedifferentiation can be noted through changes in gene expression, physiology, function within the organism, proliferative activity, or morphology. While it can be induced in a laboratory setting through processes like direct reprogramming and the production of induced pluripotent stem cells, endogenous dedifferentiation processes also exist as a component of wound healing mechanisms.
London's King's Cross railway station is temporarily closed due to overcrowding as passengers are warned not to travel by train because of disruptions caused by Storm Babet. Police launch an investigation after three men escape from HM Prison Hollesley Bay on the same day. 22 October – Storm Babet: Residents of 500 properties in Retford, Nottinghamshire are urged to evacuate as Nottinghamshire County Council declares a major flooding incident. 27 October – Sixteen people, including a prison health worker, are sentenced to prison for their part in a drugs smuggling ring operating at HM Prison Lindholme. Instances of antisemitic crime have continued to increase in London since the start of the Israel–Hamas conflict, with 408 cases occurring since 1 October, compared to 28 for the same period in 2022. 28 October – The Priory Meadow Shopping Centre in Hastings is evacuated after rain causes heavy flooding in the town. Nottingham Panthers forward Adam Johnson dies after receiving a serious cut to the neck from an ice skate during a match with the Sheffield Steelers. Cars and property are damaged after a tornado strikes Littlehampton in West Sussex. 29 October – Nine people are taken to hospital after a car crashes into a bus stop in Aldwych, central London. 30 October – Ealing Central Library is closed temporarily after bed bugs are discovered in the furnishings.
Sources: en.wikipedia.org
=== Flows with large viscosity === For flows where viscous forces are dominant i.e. slow flows with large viscosity, a viscous pressure scale μU/L is used. In the absence of a free surface, the equation obtained is
=== Fossil record === The earliest widely accepted animal fossils are rather modern-looking cnidarians, possibly from around 580 million years ago, although fossils from the Doushantuo Formation can only be dated approximately. The identification of some of these as embryos of animals has been contested, but other fossils from these rocks strongly resemble tubes and other mineralized structures made by corals. Their presence implies that the cnidarian and bilaterian lineages had already diverged. Although the Ediacaran fossil Charnia used to be classified as a jellyfish or sea pen, more recent study of growth patterns in Charnia and modern cnidarians has cast doubt on this hypothesis, leaving the Canadian polyp Haootia and the British Auroralumina as the only recognized cnidarian body fossils from the Ediacaran. Auroralumina is the earliest known animal predator. Few fossils of cnidarians without mineralized skeletons are known from more recent rocks, except in Lagerstätten that preserved soft-bodied animals. A few mineralized fossils that resemble corals have been found in rocks from the Cambrian period, and corals diversified in the Early Ordovician. These corals, which were wiped out in the Permian–Triassic extinction event about 252 million years ago, did not dominate reef construction since sponges and algae also played a major part. During the Mesozoic era, rudist bivalves were the main reef-builders, but they were wiped out in the Cretaceous–Paleogene extinction event 66 million years ago, and since then the main reef-builders have been scleractinian corals.
== Early life == Sheik was born on November 18, 1969, in Glen Ridge, New Jersey. He grew up in Montclair, New Jersey. Following his parents' divorce, he split time between his father's house in New Jersey and his mother's home in South Carolina. He was the half-brother of Broadway actress Kacie Sheik. Sheik's Juilliard-trained grandmother introduced him to the piano, and he later took up the electric guitar. By age 12, he was playing guitar with high school students in a cover band. After graduating from Phillips Academy, Andover in 1988, Sheik studied semiotics at Brown University; while at Brown, he played guitar in a band with fellow Brown student Lisa Loeb. Following his graduation from Brown in 1992, he moved to Los Angeles.
== Fecundity == Fecundity of An. gambiae depends on the detoxification of reactive oxygen species (ROS) by catalase. Reduction in catalase activity significantly reduces reproductive output of female mosquitoes, indicating that catalase plays a central role in protecting oocytes and early embryos from ROS damage.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.